A Multi-Center, Open-Label, Randomized, Phase 2b Study to Evaluate the Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma.

Trial Profile

A Multi-Center, Open-Label, Randomized, Phase 2b Study to Evaluate the Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2013

At a glance

  • Drugs BC 819 (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors BioCancell Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 28 Mar 2012 Planned number of patients changed from 150 to 70 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top